HEPA vs. ONVO, GENE, SPRC, NBY, EVAX, PRFX, ARTL, APVO, ENVB, and GLMD
Should you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Organovo (ONVO), Genetic Technologies (GENE), SciSparc (SPRC), NovaBay Pharmaceuticals (NBY), Evaxion A/S (EVAX), PainReform (PRFX), Artelo Biosciences (ARTL), Aptevo Therapeutics (APVO), Enveric Biosciences (ENVB), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical products" industry.
Hepion Pharmaceuticals vs. Its Competitors
Organovo (NASDAQ:ONVO) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.
Organovo has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.
Hepion Pharmaceuticals has a net margin of 0.00% compared to Organovo's net margin of -10,151.64%. Organovo's return on equity of -346.26% beat Hepion Pharmaceuticals' return on equity.
8.2% of Organovo shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 3.7% of Organovo shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Hepion Pharmaceuticals had 1 more articles in the media than Organovo. MarketBeat recorded 1 mentions for Hepion Pharmaceuticals and 0 mentions for Organovo. Hepion Pharmaceuticals' average media sentiment score of 0.40 beat Organovo's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.
Organovo has higher revenue and earnings than Hepion Pharmaceuticals. Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Summary
Organovo and Hepion Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get Hepion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hepion Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:HEPA) was last updated on 7/4/2025 by MarketBeat.com Staff
